Skip to main content
Figure 3 | World Journal of Surgical Oncology

Figure 3

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Figure 3

DCR of Endostar combined with PBDC versus PBDC alone for treating NSCLC. DCR, disease control rate; GP, gemcitabine + cisplatin; NP, vinorelbine + cisplatin; OR, odds ratio; PBDC, conventional platinum-based doublet chemotherapy; PP, paclitaxel + cisplatin; RT, radiotherapy; TC, paclitaxel + carboplatin; TP, docetaxel + cisplatin.

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us